Test for statin side effects launched

June 1, 2012
Some people stop taking statins because of fears over side effects. Credit: iStockphoto/Marcelo Wain

(Medical Xpress) -- A simple diagnostic test developed at Oxford University, and launched today by Massachusetts-based Boston Heart Diagnostics, will identify those at increased risk of rare but serious side effects from taking cholesterol-lowering statin drugs.

Isis Innovation, the University's technology commercialisation company, granted Boston Heart Diagnostics an exclusive US license to the test in 2011. The test is now available for license in non-US territories, including the UK.

Researchers at Oxford University's Clinical Trial Service Unit, led by Professor Rory Collins, identified the genetic biomarker SLCO1B1, which is an effective identifier of patients at increased risk of myopathy – the onset of muscle aches, pains and weakness associated with statin therapy. This condition can be extremely unpleasant and occasionally becomes very serious.

"Lowering cholesterol with statin therapy results in a substantial reduction in heart attacks, stroke and cardiovascular mortality and larger reductions in produce larger benefits," said Professor Collins. "In rare cases, myopathy occurs in association with statin therapy, especially when the statins are given at higher doses and with certain other medications. Knowledge of the SLCO1B1 marker may help to achieve the benefits of statin therapy more safely and effectively."

Boston Heart Diagnostics has now launched the Statin Induced Myopathy (SLCO1B1) Genotype test. The test classifies individuals into high risk or low risk genotypes based on the presence or absence of the SLCO1B1 .

"Of course there are any number of reasons that people ignore their healthcare provider's advice, but statin-induced myopathy can be extremely unpleasant and, for a small percentage, completely debilitating – leading many to forego taking the potentially life-saving drug," said Boston Heart Diagnostics President and CEO Susan Hertzberg.

"We are delighted to assist in bringing this important new test to the US market through an exclusive arrangement with Boston Diagnostics," said Tom Hockaday, Managing Director of Isis Innovation. "The test has the potential to allow physicians worldwide to assist patients to choose the best and safest treatment option for their particular case.'

Explore further: Statins prevent cancer in heart transplant recipients

Related Stories

Statins prevent cancer in heart transplant recipients

May 20, 2012
Statins prevent cancer and reduce death from all causes in heart transplant recipients. The findings were independent of cholesterol levels.

Intensive-dose statin therapy associated with increased risk of diabetes

June 21, 2011
An analysis of data from previously published studies indicates that intensive-dose statin therapy is associated with an increased risk of new-onset diabetes compared with moderate-dose therapy, according to a study in the ...

Recommended for you

Team finds link between backup immune defense, mutation seen in Crohn's disease

July 27, 2017
Genes that regulate a cellular recycling system called autophagy are commonly mutated in Crohn's disease patients, though the link between biological housekeeping and inflammatory bowel disease remained a mystery. Now, researchers ...

Study finds harmful protein on acid triggers a life-threatening disease

July 27, 2017
Using an array of modern biochemical and structural biology techniques, researchers from Boston University School of Medicine (BUSM) have begun to unravel the mystery of how acidity influences a small protein called serum ...

CRISPR sheds light on rare pediatric bone marrow failure syndrome

July 27, 2017
Using the gene editing technology CRISPR, scientists have shed light on a rare, sometimes fatal syndrome that causes children to gradually lose the ability to manufacture vital blood cells.

Post-stroke patients reach terra firma with new exosuit technology

July 26, 2017
Upright walking on two legs is a defining trait in humans, enabling them to move very efficiently throughout their environment. This can all change in the blink of an eye when a stroke occurs. In about 80% of patients post-stroke, ...

Molecular hitchhiker on human protein signals tumors to self-destruct

July 24, 2017
Powerful molecules can hitch rides on a plentiful human protein and signal tumors to self-destruct, a team of Vanderbilt University engineers found.

Researchers develop new method to generate human antibodies

July 24, 2017
An international team of scientists has developed a method to rapidly produce specific human antibodies in the laboratory. The technique, which will be described in a paper to be published July 24 in The Journal of Experimental ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

PeterD
not rated yet Jun 05, 2012
Only an idiot would take statins since there is no evidence that shows that these drugs help you live longer. they are a complete fraud!

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.